[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100513804":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":31,"collaborators":7,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":7,"eligibilityCriteria":39,"healthyVolunteers":35,"sex":40,"minAge":41,"maxAge":7,"enrollmentInfo":42,"targetDuration":7,"studyType":45,"phases":7,"briefSummary":46,"conditions":47,"keywords":7,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":59},{"fullName":5,"class":6},"Boryung Pharmaceutical Co., Ltd","INDUSTRY",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Shinyoung Oh","CONTACT","+82-2-708-8000","syoh@boryung.co.kr",[15],{"facility":16,"status":17,"city":18,"state":19,"zip":20,"country":21,"countryCode":7,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"Gachon University Gil Medical Center","RECRUITING","Incheon","Namdong-gu","21565","South Korea",{"type":23,"coordinates":24},"Point",[25,26],126.70515,37.45646,{"lat":26,"lon":25},[29],{"name":30,"role":11,"phone":7,"phoneExt":7,"email":7},"Ki-young Lee",{"type":32,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100513804","a-study-to-evaluate-the-efficacy-and-safety-of-dapagliflozin-in-patient-with-type-2-diabetes-mellitus-and-hypertension-100513804",false,"NCT05970237","A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension","A Multicenter, Prospective, Non-interventional, Observational Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension","Inclusion Criteria:\n\n* Those diagnosed with type 2 diabetes mellitus accompanied by hypertension who are scheduled to be administrated Trudapa Tab. or Trudapa M SR Tab.\n* Those who voluntarily signed a written personal information agreement to participate in this clinical study.\n* Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion.\n\nExclusion Criteria:\n\n* Patients with secondary hypertension: Secondary hypertension is not limited to the following diseases; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.)\n* Those who have a history of taking dapagliflozin within 4 weeks of baseline (Visit 1)\n* Those who are expected to need insulin prescription during the study period\n* Pregnant women, breast-feeding women","ALL","19 Years",{"count":43,"type":44},9000,"ESTIMATED","OBSERVATIONAL","The purpose of this clinical trial is to evaluate the efficacy and safety of dapagliflozin in patient with type 2 diabetes mellitus and hypertension",[48,49],"Diabetes Mellitus","Hypertension","2025-09-11",{"date":52,"type":53},"2025-09-15","ACTUAL",{"date":55,"type":53},"2023-07-26",{"date":57,"type":44},"2025-10-21",{"name":5,"class":6},1]